Tech Transfer eNews Blog

HJF and Citranvi sign licensing agreement to advance herpes virus vaccines


By Jesse Schwartz
Published: October 28th, 2020

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and North Carolina-based Citranvi Biosciences have signed an exclusive licensing agreement to help develop vaccines against two herpes viruses, Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV).

The licensed technology can be used to produce recombinant proteins in a multimeric form, thereby increasing the vaccines’ ability to generate protective antibodies. The technology was developed by Department of Defense researchers at the Uniformed Services University of the Health Sciences (USU) and patented by HJF under the USU-HJF Joint Office of Technology Transfer.

CMV is the most common infectious cause of brain damage and sensorineural hearing loss in infants, while EBV can lead to serious complications including liver failure, splenic rupture and hematologic disorders.

“The dangers posed by congenital CMV and EBV are significant,” says Krishna Prasad, founder of Citranvi Biosciences. “Citranvi is excited to partner with HJF toward the goal of developing vaccines.”

HJF president and CEO Joseph Caravalho comments, “HJF’s mission is to advance military medicine and part of that mandate is ensuring our nation’s warfighters are healthy and able to fulfill their mission. The hope is that this partnership with Citranvi will lead to a new vaccine to fight EBV and CMV, ultimately improving force readiness and benefiting warfighters and civilians alike.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment